Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1126 to 1140 of 2042 results for guidelines

  1. Terms and conditions

    Terms and conditions for the National Institute for Health and Care Excellence

  2. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA347

  3. Thora-3Di for assessing asthma in children (MIB122)

    NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .

    Medtech innovation briefing
    Published
    2 October 2017

  4. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    10 November 2021
    View recommendations

    Sections for TA744

  5. Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template (PMG24)

    Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template

  6. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

    Technology appraisal guidance
    Published
    6 December 2023
    View recommendations

    Sections for TA935

  7. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  8. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.

    Technology appraisal guidance
    Published
    5 August 2020
    View recommendations

    Sections for TA640

  9. Second-line maintenance therapy in children and young people (under 16):- Is maintenance therapy more effective with a paediatric low dose of ICS plus a leukotriene receptor antagonist (LTRA) or with a paediatric low dose of ICS plus a long-acting beta2 agonist (LABA) in the treatment of asthma in children and young people (under 16) who have uncontrolled asthma on a paediatric low dose of ICS alone?

    people in this guideline were made using extrapolation from the adult evidence and the consensus of the guideline...

    Research recommendation
    Published
    18 October 2018

  10. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

    Medtech innovation briefing
    Published
    25 March 2015

  11. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

    Medtech innovation briefing
    Published
    3 December 2019

  12. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  13. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE2

  14. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (HTE1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE1

  15. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

    Medtech innovation briefing
    Published
    17 December 2019